12:00 AM
Jun 05, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Maxamine histamine dihydrochloride: Phase III

MAXM presented previously reported Phase III data showing that Maxamine plus low doses of interleukin-2 (IL-2) improved survival compared to the same doses of IL-2 alone (see BioCentury, May 8). The combination led to...

Read the full 157 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >